The daily business briefing: October 22, 2020
Purdue Pharma agrees to pay $8.3 billion opioid settlement, negotiators say coronavirus relief might be passed after election, and more

- 1. OxyContin-maker Purdue Pharma to pay $8.3 billion opioid-crisis settlement
- 2. Negotiators say coronavirus relief might be passed after election
- 3. Stock futures fall as concerns about coronavirus relief continue
- 4. AstraZeneca coronavirus vaccine trial volunteer dies in Brazil
- 5. Chipotle returns to sales growth but stock falls

1. OxyContin-maker Purdue Pharma to pay $8.3 billion opioid-crisis settlement
Purdue Pharma, maker of the painkiller OxyContin, plans to plead guilty to three felony criminal charges as part of an $8.3 billion settlement over the role the company and its drug played in the opioid epidemic, the Justice Department announced Wednesday. The agreement also resolves civil charges against Purdue related to the opioid crisis, which has killed hundreds of thousands of people. Purdue admitted to lying to the Drug Enforcement Administration about its monitoring of physicians to prevent the diversion of OxyContin to illegal channels. The deal does not eliminate criminal liability of Purdue's owners, the Sackler family. Family members said they behaved "ethically and lawfully." Some state attorneys general criticized the deal by saying it let the Sacklers off too easy.
2. Negotiators say coronavirus relief might be passed after election
Treasury Secretary Steven Mnuchin and House Speaker Nancy Pelosi (D-Calif.) said Wednesday they have made more progress toward a deal on a new coronavirus relief package, but suggested it might not be passed until after Election Day. Mnuchin and Pelosi said they were narrowing their differences on a potential $2 trillion stimulus agreement but suggested there might not be a way to get enough lawmakers on board before Nov. 3. "I'm optimistic that there will be a bill. It's a question of, is it in time to pay the November rent, which is my goal, or is it going to be shortly thereafter and retroactive?" Pelosi said on MSNBC. Larry Kudlow, a top White House economic adviser, confirmed that finalizing the terms of a relief package in Congress' lame-duck session "could be a possibility."
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
3. Stock futures fall as concerns about coronavirus relief continue
U.S. stock index futures fell slightly early Thursday as uncertainty about a new coronavirus relief deal continued. Futures for the Dow Jones Industrial Average, the S&P 500, and the Nasdaq were down by about 0.3 percent several hours before the opening bell. All three of the main U.S. indexes fell on Wednesday, giving back early gains. The Dow dropped by 0.4 percent, while the S&P 500 and the tech-heavy Nasdaq fell by 0.2 percent and 0.3 percent, respectively. The market struggles came despite word from House Speaker Nancy Pelosi's spokesman that she and Treasury Secretary Steven Mnuchin were "closer to being able to put pen to paper to write legislation" on a coronavirus relief bill. The announcement by top intelligence officials that Iran and Russia were trying to interfere in the U.S. election added to the headwinds.
4. AstraZeneca coronavirus vaccine trial volunteer dies in Brazil
A volunteer in a COVID-19 vaccine trail drug-maker AstraZeneca is conducting with the University of Oxford has died in Brazil, the South American nation's National Health Surveillance Agency said Wednesday. The agency said it was formally notified Monday. The cause of death was not released, but Ian Jones, a professor of virology at the University of Reading in the United Kingdom, said it probably wasn't vaccine-related. AztraZeneca said in a statement to NBC News that the trial would continue. "We cannot comment on individual cases in an ongoing trial of the Oxford vaccine as we adhere strictly to medical confidentiality and clinical trial regulations, but we can confirm that all required review processes have been followed," the statement said.
5. Chipotle returns to sales growth but stock falls
Chipotle Mexican Grill reported Wednesday a return to quarterly sales growth despite the summertime coronavirus surge. Chipotle reported earnings of $3.76 a share after adjusting for such costs as restructuring and restaurant closures, down from $3.47 a share in the same period last year. But revenue returned to growth, totaling $1.6 billion, up from $1.4 billion a year earlier. Same-store sales jumped by 8.3 percent, exceeding analysts' expectations of a 7.3 percent gain, according to FactSet. Online sales growth of 202.5 percent led the way. The company did not provide a forecast for the current quarter, however, citing "ongoing uncertainty surrounding the future impact of COVID-19." Shares fell by 5 percent in after-hours trading following the results, after rising 1 percent in regular trading.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Harold Maass is a contributing editor at The Week. He has been writing for The Week since the 2001 debut of the U.S. print edition and served as editor of TheWeek.com when it launched in 2008. Harold started his career as a newspaper reporter in South Florida and Haiti. He has previously worked for a variety of news outlets, including The Miami Herald, ABC News and Fox News, and for several years wrote a daily roundup of financial news for The Week and Yahoo Finance.
-
Book reviews: ‘Red Scare: Blacklists, McCarthyism, and the Making of Modern America’ and ‘How to End a Story: Collected Diaries, 1978–1998’
Feature A political ‘witch hunt’ and Helen Garner’s journal entries
By The Week US Published
-
The backlash against ChatGPT's Studio Ghibli filter
The Explainer The studio's charming style has become part of a nebulous social media trend
By Theara Coleman, The Week US Published
-
Why are student loan borrowers falling behind on payments?
Today's Big Question Delinquencies surge as the Trump administration upends the program
By Joel Mathis, The Week US Published
-
'Like a sound from hell': Serbia and sonic weapons
The Explainer Half a million people sign petition alleging Serbian police used an illegal 'sound cannon' to disrupt anti-government protests
By Abby Wilson Published
-
The arrest of the Philippines' former president leaves the country's drug war in disarray
In the Spotlight Rodrigo Duterte was arrested by the ICC earlier this month
By Justin Klawans, The Week US Published
-
Ukrainian election: who could replace Zelenskyy?
The Explainer Donald Trump's 'dictator' jibe raises pressure on Ukraine to the polls while the country is under martial law
By Sorcha Bradley, The Week UK Published
-
Why Serbian protesters set off smoke bombs in parliament
THE EXPLAINER Ongoing anti-corruption protests erupted into full view this week as Serbian protesters threw the country's legislature into chaos
By Rafi Schwartz, The Week US Published
-
Who is the Hat Man? 'Shadow people' and sleep paralysis
In Depth 'Sleep demons' have plagued our dreams throughout the centuries, but the explanation could be medical
By The Week Staff Published
-
Why Assad fell so fast
The Explainer The newly liberated Syria is in an incredibly precarious position, but it's too soon to succumb to defeatist gloom
By The Week UK Published
-
Romania's election rerun
The Explainer Shock result of presidential election has been annulled following allegations of Russian interference
By Sorcha Bradley, The Week UK Published
-
Russia's shadow war in Europe
Talking Point Steering clear of open conflict, Moscow is slowly ratcheting up the pressure on Nato rivals to see what it can get away with.
By The Week UK Published